At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 185 enrolled
Drug / intervention
Siponimoddrug
Likely dose
Siponimod 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study
In Brief
A Phase 3 clinical trial evaluating Siponimod for Multiple Sclerosis and 2 related conditions. Completed, enrolled 185 participants across 55 sites in 2 countries.
Detailed Summary
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartFeb 2019
Primary CompletionJul 2022
TodayJul 2026
First PostedAug 9, 2018
Enrollment StartFeb 14, 2019
Primary CompletionJul 6, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.9 years ago
Interventions
Siponimoddrug
Siponimod 2mg tablets taken once daily